Thromboxane A2 generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction

Circulation Journal

Volumn 77, Issue 11, 2013, Pages 2786-2792

  DeFilippis, Andrew P ^a   Oloyede, Oluwasegun S ^b   Andrikopoulou, Efstathia ^e   Saenger, Amy K ^f   Palachuvattil, Joel M ^b   Fasoro, Yetunde A ^b   Guallar, Eliseo ^b   Blumenthal, Roger S ^c   Kickler, Thomas S ^d   Jaffe, Allan S ^f   Gerstenblith, Gary ^d   Schulman, Steven P ^d   Rade, Jeffrey J ^g  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Aspirin resistance; Atherothrombosis; Thromboxane

Indexed keywords

11 DEHYDRO 2,3 DINOR THROMBOXANE B2; 11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CREATININE; CYCLOOXYGENASE 1; THROMBOXANE A2; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROTHROMBOTIC MYOCARDIAL INFARCTION; CLINICAL ASSESSMENT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; THROMBOSIS;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; THROMBOSIS; THROMBOXANE A2; THROMBOXANE B2;

EID: 84886459537     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1421     Document Type: Article

References (37)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics -- 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
2. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
3. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
4. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-594.
5. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
6. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
7. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
8. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 2007; 23: 213-222.
9. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57: 1069-1077.
10. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
11. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008; 336: 195-198.
12. Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-1713.
13. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: Determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
14. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
15. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-435.
16. Olson MT, Kickler TS, Lawson JA, McLean RC, Jani J, Fitzgerald GA, et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B(2) determination with cardiovascular risk. J Thromb Haemost 2012; 10: 2462-2469.
17. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: A randomized controlled trial. JAMA 2002; 287: 1943-1951.
18. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. Am Heart J 2004; 148: 764-775.
19. US Department of Health and Human Services FaDA. AspirinWorks Test Kit {11 dehydro thromboxane B2} (urine). http://wwwaccessdatafdagov/scripts/cdrh/cfdocs/cfCLIA/Detailcfm?ID=10914. (accessed October 1, 2010).
20. Cayman Chemical Company. Aspirin effect - Detection Kit (11-dehydro Thromboxane B2 - monoclonal). Catalog no. 10010153. Package insert 100101532007: 1-11.
21. Cayman Chemical Company. 11-dehyro-TXB2 EIA kit (polyclonal). Catalog no.: 519501. Package insert 5195012009: 1-32.
22. Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 6: 1933-1943.
23. Christie D. Platelet function testing by aggregometry: Approved guidelines. Clin Lab Standards Inst 2008; H58-A 28 (31): 17-19.
24. Zack PM, Ischinger T, Aker UT, Dincer B, Kennedy HL. The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 1984; 108: 1408-1412.
25. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
26. Wallentin L. P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-1977.
27. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007-1013.
28. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
29. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GV, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63: 163-168.
30. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47: 647-656.
31. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
32. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
33. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003; 110: 281-286.
34. Ziegler BK, Kristensen SD, Vissinger H, Jensen HK, Nielsen HK, Husted SE. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: A placebo-controlled pilot trial. Thromb Res 2001; 104: 175-180.
35. Patrono C, Rocca B. Aspirin: Promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008; 28: s25-s32.
36. Nusing R, Ullrich V. Immunoquantitation of thromboxane synthase in human tissues. Eicosanoids 1990; 3: 175-180.
37. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042-12048.